Lv1
80 积分 2022-11-13 加入
Tarlatamab: First Approval
1个月前
已完结
Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer
2个月前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
2个月前
已完结
Sotatercept: First Approval
4个月前
已完结
BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: clinical development update
5个月前
已关闭
A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor
11个月前
已完结
A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies
1年前
已完结
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial
1年前
已完结
"Bloody" good factors for keeping the brain young
1年前
已完结
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response
1年前
已完结
皖公网安备34019202002308
